November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.
November is Clostridioides difficile (C diff) Awareness Month.
“Usually for antibiotic awareness you have a week,” said Dr. Teena Chopra, “But for C diff a whole month has been dedicated, for a reason.”
Each year, this Gram-positive, highly infectious and resilient bacterium casuses an estimated half a millon infections and a billion dollars in healthcare-related costs in the US alone.
To raise awareness of the high prevalence and mortality of C diff, as well as the most promising therapies, we're recapping our most relevant C diff coverage from the past month.
In the latest episode of the Contagion Community podcast, Dr. Teena Chopra discusses the global need to do more to prevent healthcare-associated infections like C difficile in vulnerable patient populations.
An easy-to-administer oral biologic kept repeat C difficile infections at bay in a new study.
The closely watched therapeutic candidate led to long-term responses in 90% of patients who benefited from the therapy.
The Peggy Lillis Foundation hopes to use the month to increase the public’s awareness of the dangers of the C difficile infection.
The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.